Journals / Medicine Science / 2021 / Cilt: 10 - Sayı: 2

Increased levels of thioredoxin and thioredoxin reductase in diabetic patients with coronary artery disease

Pages
391–395
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Also, there was a significant positive correlation between Trx and TXNIP (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The prevalence of type 2 diabetes (DM) is considered an important risk factor for coronary artery disease (CAD).
📊
Key Findings & Data:A total of 99 patients with DM were included in the study (DM + CAD n: 62 and DM n: 37.
💡
Conclusion & Impact:Also, there was a significant positive correlation between Trx and TXNIP (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

The prevalence of type 2 diabetes (DM) is considered an important risk factor for coronary artery disease (CAD). This study aimed to evaluate the relationship between CAD and thioredoxin (Trx) system and novel lipid indices in DM patients. In this case-control study, serum levels of Trx, Thioredoxin reductase (TrxR), Thioredoxin interacting protein (TXNIP), and novel lipid indices in DM undergoing coronary angiography (CAG) was investigated. A total of 99 patients with DM were included in the study (DM + CAD n: 62 and DM n: 37. Serum levels of intracellular antioxidant defense molecules, Trx and TrxR were significantly increased in patients with CAD+DM. However, TXNIP serum levels did not differ significantly between DM+CAD and DM groups. Also, there was a significant positive correlation between Trx and TXNIP (p

🔖

Cite This Article

Demir, C., Yilmaz, N., Eren, E. (2022). Increased levels of thioredoxin and thioredoxin reductase in diabetic patients with coronary artery disease. Medicine Science, Cilt: 10 - Sayı: 2, 391–395. https://ajindex.com/articles/579646

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Wang DS, Yan LY, Yang DZ, et al. Formononetin ameliorates myocardial ischemia/reperfusion injury in rats by suppressing the ROS-TXNIP-NLRP3 pathway. Biochem Biophys Res Commun. 2020; 4: pii: S0006-291X (20)30436-8.
  2. Rong J, Xu X, Xiang Y, et al. Thioredoxin-interacting protein promotes activation and inflammation of monocytes with DNA demethylation in coronary artery disease. J Cell Mol Med. 2020;24:3560-3571.
  3. Poljsak B, Milisav I. The neglected significance of "antioxidative stress". Oxid Med Cell Longev. 2012;2012:480895. Zschauer TC, Matsushima S, Altschmied J, et al. Interacting with thioredoxin1-disease or no disease? Antioxid Redox Signal. 2013;20:18:1053-62.
  4. Lee S, Kim SM, Lee RT. Thioredoxin and thioredoxin target proteins: from molecular mechanisms to functional significance. Antioxid Redox Signal. 2013;1;18:1165-207.
  5. Oliveira PVS, Laurindo FRM. Implications of plasma thiol redox in disease. Clin Sci (Lond). 2018;21;132:1257-80.
  6. Mahmood DF, Abderrazak A, El Hadri K, et al. The thioredoxin system as a therapeutic target in human health and disease. Antioxid Redox Signal. 2013;10;19:1266-303.
  7. Ren X, Zou L, Lu J, Holmgren A. Selenocysteine in mammalian thioredoxin reductase and application of ebselen as a therapeutic. Free Radic Biol Med. 2018;1;127:238-47.
  8. Miller CG, Holmgren A, Arnér ESJ, et al. NADPH-dependent and -independent disulfide reductase systems. Free Radic Biol Med. 20181;127:248-61.
  9. Gu C, Liu S, Wang H, Dou H. Role of the thioredoxin interacting protein in diabetic nephropathy and the mechanism of regulating NOD-like receptor protein 3 inflammatory corpuscle. Int J Mol Med. 2019;43:2440-50. Kariž S, Mankoč S, Petrovič D. Association of thioredoxin reductase 2 (TXNRD2) gene polymorphisms with myocardial infarction in Slovene patients with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2015;108:323-8.
  10. Zhao X, Zhang Y, Li X, et al. Variations of thioredoxin system contributes to increased susceptibility to apoptosis in cardiomyocytes of type 2 diabetic rats. Acta Biochim Biophys Sin (Shanghai). 2014;46:318-29.
  11. El Hadri K, Mahmood DF, Couchie D, et al. Thioredoxin-1 promotes anti-inflammatory macrophages of the M2 phenotype and antagonizes atherosclerosis. Arterioscler Thromb Vasc Biol. 2012;32:1445-52.
  12. Yoshihara E, Masaki S, Matsuo Y, et al. Thioredoxin/Txnip: redoxisome, as a redox switch for the pathogenesis of diseases. Front Immunol. 2014;9;4- 514. Whayne TF Jr, Parinandi N, Maulik N. Thioredoxins in cardiovascular disease. Can J P